The drug, tolebrutinib, delayed disability progression by 31% in people with a type of MS called non-relapsing secondary progressive multiple sclerosis, researchers reported in the New England Journal ...

Panelists discuss how progression independent of relapse activity (PIRA) represents a distinct pathological process involving smoldering inflammation and neurodegeneration that drives disability in ...

In people with early MS, diet may correlate with biological aging and the development of disease-related disability, study ...

Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational ...

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of ...

In a recent study published in Neurology - Neuroimmunology Neuroinflammation, researchers investigated the impact of coronavirus disease 2019 (COVID-19) on the progression of clinical disability in ...

Researchers developed a mouse model of multiple sclerosis that captures the features of progression independent of relapse ...

Please provide your email address to receive an email when new articles are posted on . Tolebrutinib was associated with a 31% reduced risk for 6-month confirmed disability progression vs. placebo.

How do we assess the needs of people with severe multiple disabilities? Unable to communicate verbally and physically, this population has nearly no possibility of expressing itself. Thanks to ...

Using eye-tracking -- a technique for recording and analyzing eye movements -- a team has shown that individuals with multiple disabilities can improve their social and emotional skills. Although ...

DEDHAM - A Dedham woman is trying to take the stigma out of disability aids. Noelle Connolly has been living with multiple sclerosis symptoms since she was 17 and was officially diagnosed at 23. "I ...

Share on Pinterest Scientists are trying to find blood biomarkers that may help predict the course of disease in MS. Betsie Van der Meer/Getty Images As of 2020, about 2.8 million people globally have ...